Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The aim of this phase IV interventional study is to evaluate variation in bone mineral density and lean and fat body composition in patients with prostate cancer without bone metastasis, treated with Degarelix. These variations are evaluated at time 0 (before starting androgen deprivation therapy with Degarelix) and after 12 months of therapy by dual-energy X-ray absorptiometry (DXA scan).
Epistemonikos ID: 4cc9076598e0a5f672ca904031c9dcfe21bce7b8
First added on: May 20, 2024